SC
CLDX icon

Stempoint Capital’s Celldex Therapeutics CLDX Stock Holding History

Stempoint Capital’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.64M Sell
178,412
-75,855
-30% -$2.45M 1.14% 28
2026
Q1 		$8.07M Buy
+254,267
New +$6.93M 1.54% 24
2024
Q3 		– Sell
-144,467
Closed -$5.35M – 56
2024
Q2 		$5.35M Buy
+144,467
New +$5.45M 1.57% 21

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Stempoint Capital's CLDX Position: Q2 2026 in Review

Stempoint Capital reduced its Celldex Therapeutics (CLDX) stake by 30% in Q2 2026, selling an estimated $2.45M and leaving 178,412 shares worth $6.64M. The position accounts for 1.14% of the portfolio, ranked #28.

Stempoint Capital first reported a position in CLDX in Q2 2024 and has held it in 3 quarters since. The position peaked at $8.07M in Q1 2026. 254 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

  • Stempoint Capital held 178,412 shares of Celldex Therapeutics worth $6.64M as of Q2 2026.
  • Stempoint Capital sold 75,855 Celldex Therapeutics shares in Q2 2026, an estimated $2.45M.
  • Celldex Therapeutics made up 1.14% of Stempoint Capital's portfolio in Q2 2026, its #28 holding.
  • Stempoint Capital first reported a position in Celldex Therapeutics in Q2 2024 and has held it in 3 quarters since.
  • Stempoint Capital's Celldex Therapeutics position peaked at $8.07M in Q1 2026.
  • 254 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on Stempoint Capital's 13F filing for Q2 2026, filed 14 Aug 2026.